Search Results 631-640 of 17363 for Cyclophosphamide

  1. Clinical trials - Oncology (Medical)

    Scottsdale/Phoenix, Ariz., Rochester, Minn. This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor ...

  2. Daratumumab in Primary Antiphospholipid Syndrome (DARE-APS) - Mayo Clinic

    Cyclophosphamide within the prior 90 days;; Immunomodulatory or immunosuppressive biologic agents, including belimumab, within the prior 90 days or 5 half ...

  3. Clinical trials - Oncology (Medical)

    This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with ...

  4. Doctors and departments - Mayo Clinic

    Mayo Clinic doctors and researchers are studying lymphoma to look for new ways to improve diagnosis and treatment for this cancer. Cancer research is conducted ...

  5. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID) - Mayo Clinic

    ... cyclophosphamide or bortezomib defined as lack of achieving complete or partial remission (see section 3.3 regarding definition). Patients who received ...

  6. Myositis Interstitial Lung Disease Nintedanib Trial - Mayo Clinic

    Cyclophosphamide within 3 months of baseline. 2. Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 ...

  7. Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab - Mayo Clinic

    The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard ...

  8. A Study of Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients with Previously Treated Multiple Myeloma or Plasma Cell Leukemia - Mayo Clinic

    Biological therapies, such as pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate or suppress the immune system in ...

  9. A Rollover Extension Program (Rep) to Evaluate the Long-Term Safety AndTolerability of Open Label Iptacopan in Adult Participants With Primary Iga Nephropathy - Mayo Clinic

    Participants treated with immunosuppressive or other immunmodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab ...

  10. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.